Table 1.

Participant characteristics

CharacteristicControls (N = 22,320) N (%)Cases (N = 22,301) N (%)Pa
Age at diagnosis/interview, mean ± SD60.6 ± 10.764.8 ± 8.0<0.0001
Family history of prostate cancer<0.0001
 No10,992 (86.1)10,300 (77.9)
 Yes1,779 (13.9)2,918 (22.1)
Gleason scoreN/A
 2–68,863 (52.6)
 75,548 (32.9)
 8–102,437 (14.5)
SEER stageN/A
 Local13,246 (72.8)
 Distant883 (4.9)
 Regional3,555 (19.6)
 Unknown503 (2.8)
PSA at diagnosis (ng/mL)N/A
 <10012,692 (95.7)
 ≥100565 (4.3)
Aggressive diseasebN/A
 No17,504 (82.1)
 Yes3,812 (17.9)
Vital status<0.0001
 Alive4,738 (72.2)13,794 (85.4)
 Prostate cancer–specific death01,233 (7.6)
 Other death1,822 (27.8)1,134 (7.0)
  • at test for a continuous variable and χ2 test for a categorical variable.

  • bAggressive disease is defined as a Gleason score of 8 to 10, PSA at diagnosis ≥100 ng/mL, distant stage, or prostate cancer–specific death.